OPY

OSI Systems (OSIS) is positioned to deliver its 10th and 11th consecutive years of adjusted EPS grow

E.l.f. Beauty (ELF) could meet the upper end of its implied fiscal Q4 outlook, but is likely to issu

Shareholders approved all meeting proposals, including the election of nine directors, ratification of Deloitte as auditor, advisory say-on-pay (every three years), and an amendment and restatement of the company’s certificate of incorporation. CEO Robert Lowenthal said Oppenheimer delivered record 2025 results with $1.6 billion in revenue and over $14 EPS, reported strong Q1 2026 momentum (including a 100% increase in investment banking revenue year-over-year), and the board raised the quarterly dividend $0.02 to $0.20. Management said a $70 million pre-tax legal accrual for the cash-sweep class-action settlement and about $22.3 million pre-tax stock-linked compensation expense drove a GAAP Q1 loss of $20.6 million, while adjusted net income was $47.5 million ($4.46/share); court approval of the settlement is expected within ~90 days. Interested in Oppenheimer Holdings, Inc.? Here are five stocks we like better. Lowe's levels up: A blueprint for tomorrow's home improvement Oppenheimer (NYSE:OPY) held its 2026 annual meeting of stockholders in a virtual format, during which shareholders elected directors, ratified the company’s auditor, approved executive compensation proposals on an advisory basis, and voted to approve an amendment and restatement to the company’s certificate of incorporation. Following the formal meeting, Chief Executive Officer Robert Lowenthal reviewed operating highlights for 2025 and early 2026, including record results, a dividend increase, and the expected resolution of cash sweep class action litigation. Chairman Albert G. Lowenthal said the company had 99,665 shares of Class B voting common stock entitled to vote as of the March 6, 2026 record date. According to the inspector of elections’ report, no Class B shares were represented in person and 97,387 shares were represented by proxy, representing about 97.7% of outstanding Class B voting shares, which the company said was sufficient for a quorum. → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook 3 gym stocks to cash in on dieters’ New Year's resolutions Shareholders approved the meeting’s proposals, with vote totals reported as follows: Election of directors: All nine nominees were elected, each receiving at least 97,385 votes in favor. The elected directors were Evan Behrens, Tim Dwyer, Paul Friedman, Jessica Glasser, Stacy Kantor, Albert Lowenthal, Robert Lowe...

SharkNinja (SN) remains well positioned to deliver on its fiscal 2026 targets, supported by continue

Oppenheimer (OPY) reported Q1 adjusted earnings Friday of $4.21 per diluted share, up from $2.54 a y

NEW YORK, May 1, 2026 /CNW/ - Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported a net loss of $20.6 million or $(1.93) per share (basic and diluted) for the first quarter of 2026, compared with net income of $30.7 million or $2.93 basic earnings per share for the first quarter of 2025. Revenue for the first quarter of 2026 was $445.1 million, an increase of 21.0%, compared to revenue of $367.8 million for the first quarter of 2025. First quarter 2026 results were adversely affected by a $70 million (pre-tax) legal accrual for the settlement of the "cash sweep" program litigation announced on April 24, 2026 and a $22.3 million (pre-tax) expense associated with a recurring liability-based employee compensation award program for financial advisors that is tied to our stock price, which increased by $16.90 per Class A share during the quarter (from $72.29 to $89.19). Adjusted net income(a), a non-GAAP measure which excludes the impact of these items, was $47.5 million or $4.46 adjusted basic earnings per share for the first quarter of 2026, compared with adjusted net income of $28.6 million or $2.74 adjusted basic earnings per share for the first quarter of 2025. Management believes these non-GAAP measures provide supplemental insight into the Firm's core operating performance. Robert S. Lowenthal, President and CEO commented, "Notwithstanding the unfavorable impact of the "cash sweep" settlement on the Company's overall results for the first quarter, the Firm's core businesses delivered solid operating results. Despite an increasingly challenging geopolitical environment, the strength of our franchise proved its ability to support clients across all business environments. The ongoing conflict with Iran disrupted global energy flows and intensified inflationary pressure on oil and gas prices, which in turn weighed negatively on the financial markets during March. As a result of the conflict, equity markets exhibited significant volatility with indices now hovering at or near their all-time highs. While the pre-tax results for our Wealth Management segment were lowered by the impact of our stock-based compensation program for financial advisors, underlying performance across the business remained solid. Commission revenues benefited from heightened market volatility, which drove elevated client trading. Although assets under managemen...

NEW YORK (AP) — NEW YORK (AP) — Oppenheimer Holdings Inc. (OPY) on Friday reported a loss of $20.6 million in its first quarter. The company, based in New York, said it had a loss of $1.93 per share. Earnings, adjusted for one-time gains and costs, came to $4.21 per share. The investment banking and broker-dealer services provider posted revenue of $445.1 million in the period. Its revenue net of interest expense was $445.1 million, beating Street forecasts. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OPY at https://www.zacks.com/ap/OPY

Ingredion Incorporated (NYSE:INGR) is included among the 10 Best Food Stocks with Highest Dividends. On April 22, Kristen Owen of Oppenheimer lowered the firm’s price recommendation on Ingredion Incorporated (NYSE:INGR) to $126 from $130. It reiterated an Outperform rating on the shares. The firm adjusted targets across the agriculture space as part of its Q1 preview. The analyst expects “healthy” Q1 results across coverage, pointing to stabilization trends before the outbreak of the Iran conflict. “Sentiment in the industry remains resilient, with all eyes on the potential for fundamentals to diverge as the effects of higher-for-longer energy and fertilizer prices ripple through our coverage,” the analyst said in a research note. Oppenheimer holds a cautious near-term stance on Ingredion. During the Q4 2025 earnings call, CFO Jim Gray said the company expects modest growth in 2026. He indicated that full-year net sales are projected to rise in the low- to mid-single-digit range, supported by stronger volume demand. He also noted that both reported and adjusted operating income are likely to increase at a low single-digit pace over the same period. The company expects full-year adjusted EPS between $11 and $11.80, based on an estimated share count of about 64 million to 65 million. On cash flow, Gray said operating cash is expected to be between $820 million and $940 million. Capital expenditures are projected in the range of $400 million to $440 million. Ingredion Incorporated (NYSE:INGR) is a global ingredient solutions provider serving customers in nearly 120 countries. The company processes grains, fruits, vegetables, and other plant-based materials into value-added ingredient solutions for food, beverage, animal nutrition, brewing, and industrial markets. While we acknowledge the potential of INGR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Monthly Dividend Stocks To Buy and 10 Best Bear Market Stocks to Invest In Right Now Disclosure: None. Follow Insider Monkey on Google News.

Meta Platforms (META) is expected to post strong Q1 revenue growth, but rising operating expenses ma

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. The updated analyst model keeps Gossamer Bio’s Fair Value estimate steady at US$3.69 per share, even as assumptions around growth, profitability and risk shift under the surface. Street commentary links these unchanged targets to a tug of war between mixed seralutinib data, regulatory uncertainty, and balance sheet questions on one side, and a differentiated mechanism with upcoming catalysts on the other. As you read on, you will see how these factors shape the evolving story and what to watch next in the Gossamer Bio narrative. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Gossamer Bio. Oppenheimer cut its target to US$3 from US$12 but still highlights a high likelihood of approval for seralutinib in pulmonary arterial hypertension, pointing to the inhaled PDGFR targeting approach and the need for additional well tolerated options. Oppenheimer points to upcoming CT FRI substudy data, Week 48 results, and an FDA interaction in June as events that could reduce uncertainty around seralutinib and potentially prompt a reassessment of the stock. Goldman Sachs, Wedbush, Leerink, and Barclays all downgraded Gossamer Bio after the Phase 3 PROSERA miss, with price targets reduced to a range of about US$0.30 to US$1, reflecting questions around the regulatory route and commercial opportunity. Leerink and H.C. Wainwright highlight regulatory uncertainty after PROSERA fell short on the primary endpoint. Barclays also flags a debt balance that is higher than current cash, and Wedbush factors in the need for debt restructuring and additional financing. H.C. Wainwright and Leerink both point out that attention has shifted to subgroup data and longer term outcomes. However, they maintain that capital and regulatory clarity are key swing factors for the equity story. Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives! We've flagged 3 risks for Gossamer Bio. See which could impact your investment. Fair Value: US$3.69 per share is unchanged, with the updated figure matching the prior estimate. Revenue Growth: Forecast revenue growth is adjusted from 52.92% to 40.02%. Net Prof...

Pool's (POOL) long-term growth profile is intact, with adjusted earnings per share and revenue antic

Freshworks Inc. (NASDAQ:FRSH) is one of the best under-the-radar stocks to buy according to hedge funds. On February 11, Citizens lowered its price target on Freshworks Inc. (NASDAQ:FRSH) from $27 to $16 and kept its Market Outperform rating on the stock. This update came after the company reported Q4 results, which beat market expectations with non-GAAP earnings per share of $0.14 compared to the consensus estimate of $0.12. Citizens also noted that Freshworks Inc.’s (NASDAQ:FRSH) Freddy AI annual recurring revenue reached $25 million in the quarter, up from $20 million in the previous quarter. Also on February 11, Oppenheimer cut its price target on Freshworks Inc. (NASDAQ:FRSH) from $18 to $15 and maintained its Outperform rating on the stock. Oppenheimer said the company reported “good” Q4 results, with support from momentum across its EX business and AI products. However, the research firm reduced its price target because of “lower peer group multiples.” Oppenheimer pointed to steady revenue growth, profit margins, and cash generation. The research firm pointed to “low multiples and strong balance sheet” and said this could support increased capital returns to shareholders. Freshworks Inc. (NASDAQ:FRSH) provides enterprise-grade, AI-assisted business software solutions for customer and employee experiences. While we acknowledge the potential of FRSH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Stocks Under $10 to Invest In Right Now and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. Disclosure: None. Follow Insider Monkey on Google News.